Akèy › Kansè Poumon ki pa ti selil › Connecticut › New Haven
Etid klinik pou Kansè Poumon ki pa ti selil nan New Haven, CT
41 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote New Haven (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Yale New Haven Hospital /ID# 271584, New Haven
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3 mi lwen
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi lwen
- ak 2 plis
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Yale Cancer Center, New Haven
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- Yale University School of Medicine ( Site 0201), New Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #62, New Haven
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- Smilow Cancer Center at Yale-New Haven ( Site 3253), New Haven
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Yale Cancer Center, New Haven
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale - New Haven Hospital - Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Yale Cancer Center, New Haven
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Yale University, Smillow Cancer Center, New Haven
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Yale University, New Haven
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Yale New Haven Hospital Yale Cancer Center, New Haven
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, New Haven
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Yale University, Yale Cancer Center, New Haven
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, West Haven · 3 mi lwen
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Ap rekriteFaz 1
- Yale Cancer Center, New Haven
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Yale Cancer Center, New Haven
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Yale Cancer Center, New Haven
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- Yale Cancer Center, New Haven
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Ap rekriteFaz 1/2
- Yale Cancer Center, New Haven
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Yale University School of Medicine, New Haven
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Yale Cancer Center, New Haven
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Yale Cancer Center, New Haven
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- Yale University, New Haven
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, New Haven
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- Yale University, New Haven
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- Yale University - Cancer Center, New Haven
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- Yale New Haven Hospital, Yale Cancer Center, New Haven
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Ap rekriteFaz 1/2
- Smilow Cancer Hospital, New Haven
- Smilow Cancer Hospital - Hamden Care Center, Hamden · 6 mi lwen
- Smilow Cancer Hospital Care Center - Guilford, Guilford · 13 mi lwen
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- Yale University School of Medicine /ID# 225707, New Haven
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mi lwen
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi lwen
- ak 2 plis
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Smilow Cancer Hospital (Yale University), New Haven
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- Yale University, New Haven
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi lwen
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi lwen
- ak 1 plis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi lwen
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi lwen
- ak 1 plis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi lwen
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi lwen
- ak 1 plis
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Smilow Cancer Hospital at Yale - New Haven, New Haven
- Yale-New Haven Hospital- Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- ak 1 plis
Repositioning Immunotherapy in VetArans With Lung Cancer
Ap rekriteFaz 2
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven · 3 mi lwen
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- Yale University, New Haven
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Yale Cancer Center, New Haven
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan New Haven
- Kansè nan tete38 etid
- Kansè (tout kalite)33 etid
- Kansè Metastatik23 etid
- Kansè poumon22 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Kansè ovè21 etid
- Kansè kolorektal20 etid
- Kansè pwostat20 etid
- Leksemi mieloïd egi17 etid
- Twoub Konsomasyon Alkòl (AUD)17 etid
- Sòvdòz Opioyid17 etid
- Kansè pankreyas16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.